Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience


Creative Commons License

Erol C., Bardakçi M., Hizal M., Kahraman S., Yekedüz E., GÜVEN D. C., ...More

Journal of Oncological Science, vol.9, no.2, pp.72-78, 2023 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 2
  • Publication Date: 2023
  • Doi Number: 10.37047/jos.2023-96148
  • Journal Name: Journal of Oncological Science
  • Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.72-78
  • Keywords: Hepatocellular carcinoma, prognostic factors, real-life experience, sorafenib
  • Hacettepe University Affiliated: Yes

Abstract

Objective: Sorafenib is the first targeted therapy for patients with advanced hepatocellular carcinoma (HCC). This multicen-ter study primarily aimed to assess real-life experiences of sorafenib in patients with advanced HCC in Türkiye and to determine the prognostic factors. Material and Methods: Patients treated with sorafenib for HCC treatment were included in a retrospective collection of demographic, clinical, and laboratory data. Overall survival (OS) and progression-free survival (PFS), safety data, and prognostic factors were analyzed. Results: A total of 147 patients receiving sorafenib from six tertiary oncology centers were included. Approximately 88.4% and 11.6% of patients were Child-Pugh (CP) classes A and B, respectively. The median PFS was 5.1 (95% CI, 4.3 to 5.9) and 2.9 months (95% CI, 2.3 to 3.5), and OS was 9.8 (95% CI, 6.4 to 13.2) and 5.3 months (95% CI, 4.1 to 6.5) in patients with CP-A and CP-B, respectively. There was a difference in OS between CP-A and B (p=<0.001). The most common adverse event was diarrhea (19.7%, Grade 1-2; 6.8%, Grade 3). The eastern cooperative oncology group (ECOG) performance score, CP score, neutrophil-lymphocyte ratio (NLR), and alpha-fetoprotein (AFP) values were found to be independent prognostic factors. Conclusion: OS and PFS were similar in routine clinical practice compared to Phase III pivotal SHARP and Asia-Pacific trials. The median survival was longer in those with a better ECOG performance score, CP-A, and lower NLR and AFP levels.